Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRUCE J ITELD

NPI
1588600894
CMS profile
1297210
Location
SLIDELL, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$18,973.28

140 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRUCE J ITELD

NPI 1588600894 · CMS profile ID 1297210

SLIDELL, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588600894?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRUCE J ITELD, NPI 1588600894, CMS profile ID 1297210. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588600894?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). BRUCE J ITELD, NPI 1588600894, CMS profile ID 1297210. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588600894?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
BRUCE J ITELD, NPI 1588600894, CMS profile ID 1297210, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1588600894?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

140 matching records · $18,973.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 140 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 140.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $5.9208/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944661495 CMS
Novartis Pharmaceuticals Corporation $5.7008/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777501 CMS
Novartis Pharmaceuticals Corporation $2.6808/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777493 CMS
PFIZER INC. $16.6507/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949201793 CMS
Novartis Pharmaceuticals Corporation $19.7407/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777485 CMS
Novartis Pharmaceuticals Corporation $15.4007/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777489 CMS
Novartis Pharmaceuticals Corporation $11.3107/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777497 CMS
AstraZeneca Pharmaceuticals LP $11.8807/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915425583 CMS
Janssen Pharmaceuticals, Inc $15.0907/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886344313 CMS
Janssen Pharmaceuticals, Inc $11.9307/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886344273 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.8707/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887464381 CMS
Novartis Pharmaceuticals Corporation $72.6707/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777397 CMS
Novartis Pharmaceuticals Corporation $11.2407/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777481 CMS
Merck Sharp & Dohme LLC $14.6506/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944663137 CMS
Novartis Pharmaceuticals Corporation $20.8206/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777477 CMS
Amgen Inc. $8.9106/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939263211 CMS
Merck Sharp & Dohme LLC $17.5706/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944655057 CMS
GlaxoSmithKline, LLC. $15.7906/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945148987 CMS
Novartis Pharmaceuticals Corporation $12.0006/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777473 CMS
Janssen Pharmaceuticals, Inc $16.5106/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886344307 CMS
Amgen Inc. $5.4906/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939263197 CMS
PFIZER INC. $16.0806/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949177469 CMS
Janssen Pharmaceuticals, Inc $10.9406/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886344295 CMS
Novartis Pharmaceuticals Corporation $15.7006/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777469 CMS
PFIZER INC. $0.6306/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949495909 CMS
PFIZER INC. $16.9005/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949177367 CMS
Novartis Pharmaceuticals Corporation $9.8105/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777465 CMS
Amgen Inc. $2,800.0005/23/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939263213 CMS
Amgen Inc. $467.0005/23/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939263215 CMS
Novartis Pharmaceuticals Corporation $13.5505/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777461 CMS
Novartis Pharmaceuticals Corporation $19.1105/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777449 CMS
Novartis Pharmaceuticals Corporation $6.5605/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777453 CMS
Novartis Pharmaceuticals Corporation $4.3505/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777457 CMS
Amgen Inc. $100.0005/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939263217 CMS
iRhythm Technologies, Inc. $11.9305/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955490669 CMS
Medtronic, Inc. $26.8505/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933449543 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.3505/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887464383 CMS
PFIZER INC. $19.7505/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949151489 CMS
PFIZER INC. $1.8405/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949190075 CMS
PFIZER INC. $2.6905/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949191891 CMS
PFIZER INC. $0.2405/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949213139 CMS
Amgen Inc. $8.3605/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939263195 CMS
PFIZER INC. $6.1805/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949350589 CMS
Esperion Therapeutics, Inc. $13.0905/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947261969 CMS
AstraZeneca Pharmaceuticals LP $12.0005/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914824369 CMS
Amryt Pharma Holdings Ltd $13.1305/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 881047407 CMS
Novartis Pharmaceuticals Corporation $11.9105/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777445 CMS
Novartis Pharmaceuticals Corporation $7.6904/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777401 CMS
Novartis Pharmaceuticals Corporation $18.6704/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893777441 CMS
PFIZER INC. $0.5904/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949188589 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $23,029.46 121
PY2020 $13,022.75 85
PY2021 $12,686.39 110
PY2022 $18,973.28 140
PY2023 $9,942.15 101
PY2024 $5,019.18 96
PY2025 $1,403.52 85

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,710.63 1
PY2025 Principal investigator $215,457.54 42
PY2024 Recipient $960.67 1
PY2024 Principal investigator $233,952.62 68
PY2023 Recipient $6,934.57 2
PY2023 Principal investigator $372,707.79 81
PY2022 Principal investigator $201,432.92 324
PY2021 Principal investigator $379,913.97 464
PY2020 Principal investigator $381,861.45 227
PY2019 Principal investigator $354,645.75 128

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220621970
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,674.70 12/01/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER RESEARCH
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190303139
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220621968
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $218.12 10/29/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.18 10/29/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.52 10/29/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.58 10/29/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $251.14 10/29/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $218.12 10/29/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.18 10/29/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.18 10/29/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $48.48 10/29/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.18 10/29/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254421
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $251.14 10/29/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $48.48 10/29/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $251.14 10/29/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $251.14 10/29/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.58 10/29/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.52 10/29/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254433
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 10/27/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220621972
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220621974
Principal investigator 1 Novartis Pharmaceuticals Corporation $98.39 10/27/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER RESEARCH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190302993
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 10/17/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220994081
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $334.67 10/09/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220791519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 10/08/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184247626
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220621960
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 10/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220621962
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 10/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220621964
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 10/01/2025 Non-covered Recipient Entity
Louisiana Heart Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220621966
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,000.00 09/18/2025 Non-covered Recipient Entity
ITELD BERNSTEIN ASSOCIATES DBA LOUISIANA HEART CENTER
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190309480
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 09/03/2025 Non-covered Recipient Entity
Louisiana Heart Ctr
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175224820
Principal investigator 1 Novartis Pharmaceuticals Corporation $30,538.48 09/03/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER RESEARCH
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) No dispute reported 06/30/2026 1190311601
Principal investigator 1 Eli Lilly and Company $5,718.00 06/03/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187884504
Principal investigator 1 Amgen Inc. $13,432.00 04/23/2025 Non-covered Recipient Entity
DRS ITELD BERNSTEIN & ASSOC DBA LA HEART CTR
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246640879
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,312.10 02/27/2025 Non-covered Recipient Entity
ITELD BERNSTEIN ASSOCIATES DBA LOUISIANA HEART CENTER
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190303513
Recipient Novartis Pharmaceuticals Corporation $2,710.63 02/04/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190293781
Principal investigator 1 Eli Lilly and Company $855.57 01/31/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187886942
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,256.00 01/30/2025 Non-covered Recipient Entity
ITELD BERNSTEIN ASSOCIATES DBA LOUISIANA HEART CENTER
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190303505
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,601.00 01/28/2025 Non-covered Recipient Entity
ITELD BERNSTEIN ASSOCIATES DBA LOUISIANA HEART CENTER
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190303515
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,217.15 01/15/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER RESEARCH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190302995
Principal investigator 1 Amgen Inc. $30,630.20 01/14/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER - HAMMOND
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246643651
Principal investigator 1 Novartis Pharmaceuticals Corporation $40,111.73 01/09/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER RESEARCH
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190302991
Principal investigator 1 Novartis Pharmaceuticals Corporation $33,786.48 01/06/2025 Non-covered Recipient Entity
LOUISIANA HEART CENTER RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190311599